BioLineRx Ltd. (BLRX) News
Filter BLRX News Items
BLRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BLRX News Highlights
- BLRX's 30 day story count now stands at 3.
- Over the past 1 day, the trend for BLRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RARE are the most mentioned tickers in articles about BLRX.
Latest BLRX News From Around the Web
Below are the latest news stories about BIOLINERX LTD that investors may wish to consider to help them evaluate BLRX as an investment opportunity.
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call TranscriptBioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript November 20, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2023 Financial Results Conference Call. All participants are presently in a listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] I would […] |
BLRX: A Series of Fortunate EventsBy John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 3Q:23 Operational and Financial Results Activity stepped up substantially following BioLineRx Ltd.’s (NASDAQ:BLRX) report of second quarter results. Shortly after the report, the FDA approved Aphexda and BioLineRx announced the closing of the Asia deal with Gloria Biosciences. Data for the collaboration with Columbia |
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates. |
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open. |
3 Tech Stocks That Wall Street Loves More Than NvidiaPurchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market. |
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesM.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia. |
3 Top Penny Stocks to Make You a Millionaire in 5 YearsPenny stocks can make you a millionaire with patience and luck especially when you follow secular trends overall |
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity InvestmentBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia. Motixafortide is a novel, high-affinity CXCR4 inhibitor that received approval for its first indication in September 2023 by the U.S. |
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced encouraging data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in |
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic CancerBioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that pilot phase data from an investigator-initiated, open-label, multicenter Phase 2 clinical trial with motixafortide in first-line pancreatic ductal adenocarcinoma (PDAC) will be presented at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts, Septe |